30 August 2016

Hydrodec hails transformer deal

Robert Tyerman

Profitability is now in sight claims 'green' oil technology hopeful Hydrodec following a bulk order for its 'Superfine' transformer oil.

AIM-quoted Hydrodec, set up to commercialise Australian technology to remove harmful contaminants in oil refining, says written acceptance from a major transformer manufacturer Down Under and conditional acceptance from another for bulk use of Superfine could ensure a firm market for at least half the capacity of Hydrodec's newly-commissioned refining plant in New South Wales. That, says the company, should generate annual revenues of £1.8 million, underpinned by feedstock supply commitments from major utilities.

John Gunn, the former City tycoon-turned young company backer who chairs Hydrodec, says the company, which lost nearly £6 million last year, will now be 'cash-flow positive next month and profitable in the fourth quarter'. The New South Wales plant is 'on time, and under budget' and should reach 80 per cent capacity by the end of the year and hit its full 20,000-litres-a-day potential by the first quarter of 2007.

He says the contracts 'go on', without a set termination date, and argues that Superfine faces a 'virtuous circle'. It is 'very "green" and self-sustaining': once used or filtered, it can be re-used and re-refined and 'we will refresh it and give it back over the long term.

'We have done the tests', explains Gunn, 'and the product comes up better than new after this process, with even less sulphur second time round'. With a management team boasting senior experience at chemical giants Dow , Du Pont and ICI, he says Hydrodec now intends to build a new plant and is weighing whether to site it in the USA, Japan, Turkey or Germany.

Gunn insists Hydrodec, which ended last year with £3.3 million cash and put a value of £7.3 million on its patented technology, is not looking for joint venture partners. 'We will need no new money until we have to build the new plant', he asserts.

At 28.75p, Hydrodec is a long-term gamble, which could pay off handsomely if present hopes are realised.

Growth Company Investor’s award-winning team offer outstanding share recommendation performance. Get immediate access to all these recommendations – click here.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Retailers getting One View of their customers

One View listed on AIM via a reverse takeover back in March. It has developed software that provides retailers with a combined view of their customers history in both online and in-store shopping channels. This sort of digital engagement is a big opportunity for retailers to boost their sales.

Angle moves into the clinical trial stage

Angle is making good progress with its ‘Parsortix’ system which uses a precision-etched cassette to ‘sieve’ patient blood samples and capture cancerous tumour cells. The first major trial is now underway in ovarian cancer, led by the University of Vienna.

StatPro benefiting from a Revolution

StatPro shares have done well over the last month with the stock market giving the company credit for the growth in its new ‘Revolution’ product.

Tracsis signs key US deal

Transportation software specialist Tracsis has won a significant contract in the US. This looks like it could be a breakthrough which opens up the vast North American railroad market to this Leeds based company.

MedaPhor expands in ultrasound

MedaPhor came to the market two years ago and the £14 million market cap’s shares have done little since. However a couple of recent developments suggest they are worth keeping an eye on.

ScS sees no slowdown in sofas

ScS Group confirms it hasn't seen a slowdown in demand post-Brexit. Momentum has continued since the update in early June, with like-for-like sales order intake of 14.8 per cent for the first financial year ending in July.

More News